CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals.
Prog Mol Biol Transl Sci
; 181: 185-229, 2021.
Article
de En
| MEDLINE
| ID: mdl-34127194
ABSTRACT
Clustered regularly interspaced short palindromic repeat-Cas9 (CRISPR/Cas9), derived from bacterial and archean immune systems, has received much attention from the scientific community as a powerful, targeted gene editing tool. The CRISPR/Cas9 system enables a simple, relatively effortless and highly specific gene targeting strategy through temporary or permanent genome regulation or editing. This endonuclease has enabled gene correction by taking advantage of the endogenous homology directed repair (HDR) pathway to successfully target and correct disease-causing gene mutations. Numerous studies using CRISPR support the promise of efficient and simple genome manipulation, and the technique has been validated in in vivo and in vitro experiments, indicating its potential for efficient gene correction at any genomic loci. In this chapter, we detailed various strategies related to gene editing using the CRISPR/Cas9 system. We also outlined strategies to improve the efficiency of gene correction via the HDR pathway and to improve viral and non-viral mediated gene delivery methods, with an emphasis on their therapeutic potential for correcting genetic disorder in humans and other mammals.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Systèmes CRISPR-Cas
/
Édition de gène
Limites:
Animals
/
Humans
Langue:
En
Journal:
Prog Mol Biol Transl Sci
Sujet du journal:
BIOLOGIA MOLECULAR
Année:
2021
Type de document:
Article
Pays d'affiliation:
Corée du Sud